This inventor holds 4 USPTO granted patents and 1 EPO patent. Top assignee: Novacta Biosystems Limited. Active years: 2009-2014.
Location History:
- Hatfield, GB (2009)
- Hertfordshire, GB (2011 - 2014)
Company Filing History:
Years Active: 2009-2014
Title: Steven Boakes - Pioneering Innovator in Lantibiotic Biosynthesis
Introduction:
Steven Boakes is a talented inventor based in Hertfordshire, Great Britain, with a strong passion for biochemistry and pharmaceuticals. With an impressive portfolio of four patents, his groundbreaking work in the field of lantibiotic biosynthesis has garnered attention and recognition in the scientific community.
Latest Patents:
Boakes' latest patents showcase his expertise in lantibiotic biosynthetic gene clusters. The patents describe the characterization of the biosynthetic gene cluster for the lantibiotic actagardine, identification of a novel variant of actagardine, and methods for the production and use of actagardine and its variants. These innovations have the potential to revolutionize antibiotic development and improve healthcare outcomes.
Career Highlights:
Currently employed at Novacta Biosystems Limited, Steven Boakes plays a vital role in driving innovation and discovery within the company. His dedication to advancing lantibiotic research has led to significant advancements in the field, positioning him as a key player in the development of novel pharmaceutical solutions.
Collaborations:
Boakes collaborates closely with esteemed colleagues such as Jesus Cortes Bargallo and Michael John Dawson. Together, they form a dynamic team that combines their diverse skills and expertise to push the boundaries of lantibiotic research and develop innovative solutions for the pharmaceutical industry.
Conclusion:
In conclusion, Steven Boakes stands out as a pioneering innovator in lantibiotic biosynthesis, leveraging his extensive knowledge and creativity to drive impactful change in the healthcare sector. With a strong track record of patents and a collaborative spirit, Boakes continues to shape the future of antibiotic development and pharmaceutical innovation.